222 related articles for article (PubMed ID: 26913966)
1. Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
Cencini E; Fabbri A; Bocchia M
Br J Haematol; 2017 Mar; 176(5):831-833. PubMed ID: 26913966
[No Abstract] [Full Text] [Related]
2. Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.
Garciaz S; Harel S; Amorim S; Bouabdallah R; Thieblemont C; Brice P
Br J Haematol; 2016 Nov; 175(4):735-737. PubMed ID: 26685097
[No Abstract] [Full Text] [Related]
3. Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma.
Bond DA; Dotson E; Awan FT; Baiocchi RA; Blum KA; Maddocks K
Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):e123-e128. PubMed ID: 30594446
[No Abstract] [Full Text] [Related]
4. Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage.
Torka P; Przespolewski E; Evens AM
JCO Oncol Pract; 2022 Jul; 18(7):491-497. PubMed ID: 35254922
[TBL] [Abstract][Full Text] [Related]
5. PET-adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH-05 trial.
Pavlovsky A; Fernandez I; Kurgansky N; Prates V; Zoppegno L; Negri P; Milone G; Cerutti I; Zabaljauregui S; Mariano R; Grecco HF; Basquiera AL; Saba S; Rudoy S; Sackmann F; Castano V; Remaggi G; Cabrejo M; Roveri E; Casale MF; Cabane V; Taus R; Venturini C; Sakamoto F; Varela AI; Riddick M; Pavlovsky S;
Br J Haematol; 2019 Jun; 185(5):865-873. PubMed ID: 30864146
[TBL] [Abstract][Full Text] [Related]
6. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study.
Hutchings M; Radford J; Ansell SM; Illés Á; Sureda A; Connors JM; Sýkorová A; Shibayama H; Abramson JS; Chua NS; Friedberg JW; Kořen J; LaCasce AS; Molina L; Engley G; Fenton K; Jolin H; Liu R; Gautam A; Gallamini A
Hematol Oncol; 2021 Apr; 39(2):185-195. PubMed ID: 33462822
[TBL] [Abstract][Full Text] [Related]
7. ABVD plus rituximab
Strati P; Fanale MA; Oki Y; Turturro F; Fayad LE; Bartlett NL; Gladstone DE; Kasamon YL; Portlock CS; Wilson WH; Goy A; Younes A; Lee HJ
Haematologica; 2019 Feb; 104(2):e65-e67. PubMed ID: 30190343
[No Abstract] [Full Text] [Related]
8. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
[TBL] [Abstract][Full Text] [Related]
9. [Diffuse large B-cell lymphoma following nodular lymphocyte predominant Hodgkin's lymphoma: report of a case].
Chen DB; Wang Y; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):635-6. PubMed ID: 21092597
[No Abstract] [Full Text] [Related]
10. Feasibility and efficacy of dose-dense and dose-intense ABVD for high-risk patients with advanced Hodgkin lymphoma.
D'Arco AM; Califano C; Barone L; Belsito Petrizzi V; Iovino V; Langella M; Maglione V; Rivellini F; De Lorenzo S
Br J Haematol; 2015 Nov; 171(4):662-5. PubMed ID: 25873239
[No Abstract] [Full Text] [Related]
11. How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen?
Canellos GP; Duggan D; Johnson J; Niedzwiecki D
J Clin Oncol; 2004 Apr; 22(8):1532-3. PubMed ID: 15084636
[No Abstract] [Full Text] [Related]
12. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.
Behringer K; Goergen H; Hitz F; Zijlstra JM; Greil R; Markova J; Sasse S; Fuchs M; Topp MS; Soekler M; Mathas S; Meissner J; Wilhelm M; Koch P; Lindemann HW; Schalk E; Semrau R; Kriz J; Vieler T; Bentz M; Lange E; Mahlberg R; Hassler A; Vogelhuber M; Hahn D; Mezger J; Krause SW; Skoetz N; Böll B; von Tresckow B; Diehl V; Hallek M; Borchmann P; Stein H; Eich H; Engert A; ; ;
Lancet; 2015 Apr; 385(9976):1418-27. PubMed ID: 25539730
[TBL] [Abstract][Full Text] [Related]
13. Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
Arakelyan N; Jais JP; Delwail V; Brière J; Moles-Moreau MP; Sénécal D; Berthou C; Desablens B; Colonna P; Andrieu JM;
Cancer; 2010 Sep; 116(17):4054-62. PubMed ID: 20564152
[TBL] [Abstract][Full Text] [Related]
14. [Resistance to first line chemotherapy treatment in a patient diagnosed of nodular lymphocyte-predominant Hodgkin's lymphoma identified by 18F-FDG PET/CT: diagnostic and therapeutic implications].
Banzo J; Ubieto MA; Giraldo P; Razola P; Prats E; Tardin L; Santapau A; Parra A; Rambalde EF; Velilla J
Rev Esp Med Nucl Imagen Mol; 2012; 31(2):89-92. PubMed ID: 21620527
[TBL] [Abstract][Full Text] [Related]
15. Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.
Stamatoullas A; Brice P; Bouabdallah R; Mareschal S; Camus V; Rahal I; Franchi P; Lanic H; Tilly H
Br J Haematol; 2015 Jul; 170(2):179-84. PubMed ID: 25891777
[TBL] [Abstract][Full Text] [Related]
16. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
17. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
18. Advanced Hodgkin's disease: ABVD is better, yet is not good enough!
Diehl V
J Clin Oncol; 2003 Feb; 21(4):583-5. PubMed ID: 12586791
[No Abstract] [Full Text] [Related]
19. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
[TBL] [Abstract][Full Text] [Related]
20. Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
Arakelyan N; Berthou C; Desablens B; de Guibert S; Delwail V; Moles MP; Quittet P; Jais JP; Colonna P; Andrieu JM;
Cancer; 2008 Dec; 113(12):3323-30. PubMed ID: 18988286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
